Inhibition of Aurora B by CCT137690 sensitizes colorectal cells to radiotherapy

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Wu, Xiaoyu ^a   Liu, Wentao ^b   Cao, Qinhong ^a   Chen, Che ^a   Chen, Zhiwei ^a   Xu, Zhe ^a   Li, Weisu ^a   Liu, Fukun ^a   Yao, Xuequan ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Aurora B; CCT137690; Colorectal cancer; Radiotherapy

Indexed keywords

AURORA A KINASE; AURORA B KINASE; CCT 137690; RADIOSENSITIZING AGENT; SURVIVIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL DESTRUCTION; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CHEMORADIOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; IC 50; IONIZATION; LOW ENERGY RADIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION EXPOSURE;

AURORA KINASE B; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL NEOPLASMS; HUMANS; IMIDAZOLES; INHIBITORY CONCENTRATION 50; PYRIDINES; RADIATION TOLERANCE;

EID: 84892992073     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-33-13     Document Type: Article

References (37)

1. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. Kamangar F, Dores GM, Anderson WF, J Clin Oncol 2006 24 2137 2150 10.1200/JCO.2005.05.2308 16682732 (Pubitemid 46655601)
2. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
3. Search for novel target molecules for the effective treatment or prevention of colorectal cancer. Tsujii M, Digestion 2012 85 99 102 10.1159/000334678 22269287
4. Epidemiology of gastroenterologic cancer in Henan Province, China. Lu JB, Sun XB, Dai DX, Zhu SK, Chang QL, Liu SZ, Duan WJ, World J Gastroenterol: WJG 2003 9 2400 2403
5. Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Yang L, Parkin DM, Li LD, Chen YD, Bray F, Br J Cancer 2004 90 2157 2166 15150609 (Pubitemid 38869723)
6. Increasing incidence of colorectal cancer in Asia: implications for screening. Sung JJ, Lau JY, Goh KL, Leung WK, Asia Pacific Working Group on Colorectal C, Lancet Oncol 2005 6 871 876 10.1016/S1470-2045(05)70422-8 16257795 (Pubitemid 41614799)
7. Epidemiology of colorectal cancer in Asia. Yee YK, Tan VP, Chan P, Hung IF, Pang R, Wong BC, J Gastroenterol Hepatol 2009 24 1810 1816 10.1111/j.1440-1746.2009.06138.x 20002940
8. Copy number increase of aurora kinase A in colorectal cancers: a correlation with tumor progression. Zhang C, Fang Z, Xiong Y, Li J, Liu L, Li M, Zhang W, Wan J, Acta Biochim Biophys Sin 2010 42 834 838 10.1093/abbs/gmq088 20929925
9. Drosophila Aurora-A is required for centrosome maturation and actin-dependent asymmetric protein localization during mitosis. Berdnik D, Knoblich JA, Curr Biol 2002 12 640 647 10.1016/S0960-9822(02)00766-2 11967150 (Pubitemid 34315847)
10. A combined approach of neoadjuvant chemotherapy and surgery for colorectal liver metastases. Esposito A, Mancini R, Ettorre G, Garufi C, Saracca E, Arcieri S, Cosimelli M, J Exp Clin Can Res: CR 2003 22 197 202 (Pubitemid 38436457)
11. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. Marumoto T, Honda S, Hara T, Nitta M, Hirota T, Kohmura E, Saya H, J Biol Chem 2003 278 51786 51795 10.1074/jbc.M306275200 14523000 (Pubitemid 38020425)
12. Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Baba Y, Nosho K, Shima K, Irahara N, Kure S, Toyoda S, Kirkner GJ, Goel A, Fuchs CS, Ogino S, Neoplasia 2009 11 418 425 19412426
13. Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer. Dotan E, Meropol NJ, Zhu F, Zambito F, Bove B, Cai KQ, Godwin AK, Golemis EA, Astsaturov I, Cohen SJ, Br J Cancer 2012 106 748 755 10.1038/bjc.2011.587 22240781
14. High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. Nishida N, Nagasaka T, Kashiwagi K, Boland CR, Goel A, Cancer Biol Ther 2007 6 525 533 10.4161/cbt.6.4.3817 17457043 (Pubitemid 47328326)
15. Aurora kinase expression in colorectal adenocarcinoma: correlations with clinicopathological features, p16 expression, and telomerase activity. Lam AK, Ong K, Ho YH, Hum Pathol 2008 39 599 604 10.1016/j.humpath.2007.09.001 18284933
16. Nuclear Aurora B and cytoplasmic Survivin expression is involved in lymph node metastasis of colorectal cancer. Tuncel H, Shimamoto F, Kaneko Guangying Qi H, Aoki E, Jikihara H, Nakai S, Takata T, Tatsuka M, Oncol Lett 2012 3 1109 1114 22783401
17. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, Winder T, Hu-Lieskoven S, Iqbal S, Danenberg KD, et al. Pharmacogenomics J 2013 13 173 180 10.1038/tpj.2011.61 22231565
18. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays. Manfredi MG, Ecsedy JA, Chakravarty A, Silverman L, Zhang M, Hoar KM, Stroud SG, Chen W, Shinde V, Huck JJ, et al. Clin Can Res: an Official Journal of the American Association for Cancer Research 2011 17 7614 7624 10.1158/1078-0432.CCR-11-1536
19. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel. Shimomura T, Hasako S, Nakatsuru Y, Mita T, Ichikawa K, Kodera T, Sakai T, Nambu T, Miyamoto M, Takahashi I, et al. Mol Cancer Ther 2010 9 157 166 20053775
20. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, Graham JA, Demur C, Hercend T, Diu-Hercend A, et al. Nat Med 2004 10 262 267 10.1038/nm1003 14981513 (Pubitemid 38667616)
21. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello P, et al. Mol Cancer Ther 2007 6 3158 3168 10.1158/1535-7163.MCT-07-0444 18089710
22. AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis. Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, et al. Clin Can Res: An Official Journal of the American Association for Cancer Research 2007 13 3682 3688 10.1158/1078-0432.CCR-06-2979 (Pubitemid 46955132)
23. Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cammareri P, Scopelliti A, Todaro M, Eterno V, Francescangeli F, Moyer MP, Agrusa A, Dieli F, Zeuner A, Stassi G, Cancer Res 2010 70 4655 4665 10.1158/0008-5472.CAN-09-3953 20460511
24. Aurora-A activation, correlated with hypoxia-inducible factor-1alpha, promotes radiochemoresistance and predicts poor outcome for nasopharyngeal carcinoma. Wan XB, Fan XJ, Huang PY, Dong D, Zhang Y, Chen MY, Xiang J, Xu J, Liu L, Zhou WH, et al. Cancer Sci 2012 103 1586 1594 10.1111/j.1349-7006.2012. 02332.x 22587416
25. Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Guan Z, Wang XR, Zhu XF, Huang XF, Xu J, Wang LH, Wan XB, Long ZJ, Liu JN, Feng GK, et al. Cancer Res 2007 67 10436 10444 10.1158/0008-5472.CAN-07-1379 17974987 (Pubitemid 350070819)
26. Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells. Venkataraman S, Alimova I, Tello T, Harris PS, Knipstein JA, Donson AM, Foreman NK, Liu AK, Vibhakar R, J Neuro Oncol 2012 107 517 526 10.1007/s11060-011-0795-y
27. Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests. Kim KW, Mutter RW, Willey CD, Subhawong TK, Shinohara ET, Albert JM, Ling G, Cao C, Gi YJ, Lu B, Int J Radiat Oncol Biol Phys 2007 67 1519 1525 10.1016/j.ijrobp.2006.12.018 17394948 (Pubitemid 46467182)
28. Inhibiting the aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell lines. Sak A, Stuschke M, Groneberg M, Kubler D, Pottgen C, Eberhardt WE, Int J Radiat Oncol Biol Phys 2012 84 492 499 10.1016/j.ijrobp.2011.12.021 22381900
29. Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. Bavetsias V, Large JM, Sun C, Bouloc N, Kosmopoulou M, Matteucci M, Wilsher NE, Martins V, Reynisson J, Atrash B, et al. J Med Chem 2010 53 5213 5228 10.1021/jm100262j 20565112
30. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Faisal A, Vaughan L, Bavetsias V, Sun C, Atrash B, Avery S, Jamin Y, Robinson SP, Workman P, Blagg J, et al. Mol Cancer Ther 2011 10 2115 2123 10.1158/1535-7163.MCT-11-0333 21885865
31. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns. Moore AS, Faisal A, de Castro Gonzalez D, Bavetsias V, Sun C, Atrash B, Valenti M, de Haven Brandon A, Avery S, Mair D, et al. Leukemia 2012 26 1462 1470 10.1038/leu.2012.52 22354205
32. Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Krishnan S, Janjan NA, Skibber JM, Rodriguez-Bigas MA, Wolff RA, Das P, Delclos ME, Chang GJ, Hoff PM, Eng C, et al. Int J Radiat Oncol Biol Phys 2006 66 762 771 10.1016/j.ijrobp.2006.05.063 17011451 (Pubitemid 44436703)
33. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. Longley DB, Allen WL, Johnston PG, Biochim Biophys Acta 2006 1766 184 196 16973289
34. Aurora B confers cancer cell resistance to TRAIL-induced apoptosis via phosphorylation of survivin. Yoon MJ, Park SS, Kang YJ, Kim IY, Lee JA, Lee JS, Kim EG, Lee CW, Choi KS, Carcinogenesis 2012 33 492 500 10.1093/carcin/bgr298 22159225
35. Marked upregulation of Survivin and Aurora-B kinase is associated with disease progression in the myelodysplastic syndromes. Yoshida A, Zokumasu K, Wano Y, Yamauchi T, Imamura S, Takagi K, Kishi S, Urasaki Y, Tohyama K, Ueda T, Haematologica 2012 97 1372 1379 10.3324/haematol.2011.055681 22419576
36. The Aurora A and B kinases are up-regulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets. de Paula Careta F, Gobessi S, Panepucci RA, Bojnik E, de Oliveira Morato F, Mazza Matos D, Falcao RP, Laurenti L, Zago MA, Efremov DG, Haematologica 2012 97 1246 1254 10.3324/haematol.2011.054668 22331265
37. High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer. Erpolat OP, Gocun PU, Akmansu M, Karakus E, Akyol G, Strahlenther Onkol 2012 188 248 254 10.1007/s00066-011-0042-7 22311150